Literature DB >> 8136810

[Polyarthritis in 4 patients treated with intravesical BCG-therapy for carcinoma of the bladder].

N Belmatoug1, S Levy-Djebbour, T Appelboom, C De Gennes, A P Peltier, O Meyer, M F Kahn, C Carbon.   

Abstract

Intravesical administration of Calmette-Guérin bacillus (BCG) is effective in the treatment of superficial bladder carcinoma. Transient arthritis or migratory arthralgia has been reported in 0.5% of cases. The authors report on four men (mean age 65 years), who developed an oligoarthritis in three cases after the 2nd, 5th, and 6th weekly instillation of Pasteur BCG, respectively, and symmetrical polyarthritis in one after 48 BCG instillations over a three-year period. Joints involved were the knees (3/4), ankles (3/4), shoulders (1/4), wrists, and hands (1/4). Features included morning stiffness and local evidence of inflammation. All four patients had an elevated erythrocyte sedimentation rate and negative tests for rheumatoid factor. Neutrophils were the main cell type in synovial fluid. Synovial biopsy performed in two cases revealed non-specific inflammation. Erosions of the metatarsophalangeal joints were observed in one patient. Locoregional or systemic symptoms included transient fever (3/4), cystitis (4/4), urethritis (1/4), epididymoorchitis (2/4), conjunctivitis (1/4), and pleural effusion with pericarditis (1/4). The BCG was recovered from an epididymal specimen in one patient. Two patients were positive for the HLA B27 antigen. Outcome was favorable in every case (range: 15 days-6 months) after discontinuation of BCG therapy and administration of isoniazid, rifampin, and prednisone (3 patients) or NSAID (1 patient). Various pathogenic hypotheses for BCG-induced arthritis are discussed, including infection, immune responses to heat shock proteins, and reactive arthritis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136810

Source DB:  PubMed          Journal:  Rev Rhum Ed Fr        ISSN: 1169-8330


  4 in total

Review 1.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

Review 2.  Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.

Authors:  A Lopez-Beltran; R J Luque; R Mazzucchelli; M Scarpelli; R Montironi
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

Review 3.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

4.  Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.

Authors:  Paula Cíntia Machado Sampaio; Yan Garcia Lira; Hellen Yuki Umemura Ribeiro; Fernanda de Paula Moreira; Maitê Silva Martins Gadelha; Sérgio Ferreira Santos da Cruz
Journal:  BMC Res Notes       Date:  2017-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.